cAMeLot-2_AML3001

Hematological neoplasms
Acute myeloid leukemia
First-Line-Therapy (Metastatic Disease/Hematology)
A phase 3 randomized, double-blind, placebo-controlled, study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy
A phase 3 randomized, double-blind, placebo-controlled, study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy